Home
Scholarly Works
P-203 Rationale and design of three ongoing phase...
Journal article

P-203 Rationale and design of three ongoing phase 1/2 trials of modakafusp alfa, an innate immunity enhancer, in patients with multiple myeloma: The innovate clinical development program

Authors

Mian H; Touzeau C; Holstein S; Kingsley E; Vogl D; Zuniga R; Kim K; Suryanarayan K; Wang S; Thesillat-Versmee L

Journal

Clinical Lymphoma Myeloma & Leukemia, Vol. 23, ,

Publisher

Elsevier

Publication Date

September 1, 2023

DOI

10.1016/s2152-2650(23)01821-9

ISSN

2152-2650

Contact the Experts team